文献速递神经肿瘤

5-氨基乙酰丙酸与荧光素钠用于高级别胶质瘤术中肿瘤显影的比较:单中心回顾性研究

Comparison of 5-aminolevulinic acid and sodium fluorescein for intraoperative tumor visualization in patients with high-grade gliomas: a single-center retrospective study.
PubMed 文献 · J Neurosurg · 2019-10-04

该单中心回顾性研究纳入209例高级别胶质瘤患者,比较5-氨基乙酰丙酸(5-ALA)与荧光素钠引导手术的切除程度及生存。5-ALA组158例、荧光素钠组51例,中位随访分别为46.7个月和21.2个月。两组容积评估中位切除程度无显著差异(96.9% vs 97.4%,p=0.46),荧光素钠组中位调整无进展生存期9.2个月 vs 5-ALA组8.7个月(p=0.03),总生存期差异未达显著(19.7 vs 14.8个月,p=0.06)。作者认为荧光素钠可作为5-ALA的可行替代。

要点

  • 5-ALA组与荧光素钠组容积评估中位切除程度无显著差异(96.9% vs 97.4%,p=0.46)。
  • 荧光素钠组中位调整无进展生存期9.2个月 vs 5-ALA组8.7个月(p=0.03)。
  • 两组中位总生存期差异未达统计学显著(荧光素钠组19.7个月 vs 5-ALA组14.8个月,p=0.06)。

核心结论

  • 荧光素钠可作为5-ALA用于脑肿瘤手术术中荧光引导的可行替代方案。
  • 亟需开展对比性、前瞻性及随机研究。

研究设计与样本

  • 单中心回顾性研究,纳入209例高级别胶质瘤患者。
  • 2012年至2017年间使用5-ALA或荧光素钠进行切除术。
  • 5-ALA组158例,荧光素钠组51例。
  • 切除程度通过术后早期与术前MRI肿瘤体积差值评估。
  • 采用调整Cox比例风险模型分析无进展生存期和总生存期。

主要发现

  • 5-ALA组中位随访46.7个月,荧光素钠组中位随访21.2个月。
  • 协变量分布均衡。
  • 容积评估中位切除程度:5-ALA组96.9% vs 荧光素钠组97.4%(p=0.46),无统计学显著差异。
  • 残留肿瘤体积小于0.175 cm³的患者比例:5-ALA组29.5% vs 荧光素钠组36.2%(p=0.39),无统计学显著差异。
  • 中位总生存期:5-ALA组14.8个月 vs 荧光素钠组19.7个月(p=0.06);中位调整无进展生存期:5-ALA组8.7个月 vs 荧光素钠组9.2个月(p=0.03)。

临床怎么用

  • 作者认为荧光素钠可作为5-ALA用于脑肿瘤手术术中荧光引导的可行替代方案。
  • 作者指出亟需开展对比性、前瞻性及随机研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Maximal safe resection is an important surgical goal in the treatment for high-grade gliomas. Fluorescent dyes help the surgeon to distinguish malignant tissue from healthy. The aims of this study were 1) to compare the 2 fluorescent dyes 5-aminolevulinic acid (5-ALA) and sodium fluorescein (fluorescein) regarding extent of resection, progression-free survival, and overall survival; and 2) to assess the influence of other risk factors on clinical outcome and screen for potential disadvantages of the dyes. METHODS: A total of 209 patients with high-grade gliomas were included in this retrospective study. Resections were performed in the period from 2012 to 2017 using 5-ALA or fluorescein. Extent of resection was assessed as the difference in tumor volume between early postoperative and preoperative MRI studies. Tumor progression-free survival and overall survival were analyzed using an adjusted Cox proportional hazards model. RESULTS: One hundred fifty-eight patients were operated on with 5-ALA and 51 with fluorescein. The median duration of follow-up was 46.7 and 21.2 months, respectively. Covariables were evenly distributed. There was no statistically significant difference in volumetrically assessed median extent of resection (96.9% for 5-ALA vs 97.4% for fluorescein, p = 0.46) or the percentage of patients with residual tumor volume less than 0.175 cm3 (29.5% for 5-ALA vs 36.2% for fluorescein, p = 0.39). The median overall survival was 14.8 months for the 5-ALA group and 19.7 months for the fluorescein group (p = 0.06). The median adjusted progression-free survival was 8.7 months for the 5-ALA group and 9.2 months for the fluorescein group (p = 0.03). CONCLUSIONS: Fluorescein can be used as a viable alternative to 5-ALA for intraoperative fluorescent guidance in brain tumor surgery. Comparative, prospective, and randomized studies are much needed.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Hansen RW, Pedersen CB, Halle B, et al. Comparison of 5-aminolevulinic acid and sodium fluorescein for intraoperative tumor visualization in patients with high-grade gliomas: a single-center retrospective study. J Neurosurg. 2019. PMID: 31585425. doi:10.3171/2019.6.JNS191531

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。